Microgynon (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol and levonorgestrel act on estrogen and progesterone receptors to suppress the hypothalamic‑pituitary‑ovarian axis, preventing the luteinising hormone surge that triggers ovulation. The progestogen also thickens cervical mucus, while the estrogen modifies the endometrial lining, together reducing the chance of fertilisation and implantation.

The prescribed dose of Microgynon is determined by the treating healthcare professional. The product is supplied as a tablet containing 30 µg ethinylestradiol and 150 µg levonorgestrel, and the prescriber will advise the appropriate daily regimen based on individual clinical assessment.

Microgynon is classified as pregnancy category X, meaning it must not be used during pregnancy because it can cause harm to the fetus. It is also not recommended while breastfeeding, as hormonal components may pass into breast milk and affect the infant. Women should discontinue use if pregnancy is confirmed.

To order Microgynon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Microgynon contains a low‑dose estrogen (30 µg ethinylestradiol) combined with levonorgestrel, a second‑generation progestogen. Compared with higher‑dose formulations, it may have a slightly lower risk of estrogen‑related side effects while maintaining contraceptive efficacy. Its safety profile and dosing schedule are similar to other low‑dose combined pills, but individual tolerability can vary.

Microgynon tablets should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Microgynon is taken orally, usually once daily at the same time each day. The tablet is swallowed with water and should be started according to the prescribing clinician’s instructions, typically on the first day of the menstrual period or after a hormone‑free interval.

The most serious risks include thromboembolic events such as deep vein thrombosis and pulmonary embolism, as well as rare but severe allergic reactions. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should avoid use and discuss alternatives with their healthcare provider.

Microgynon is contraindicated in women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or are smokers over 35 years of age. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.